肿瘤细胞治疗研究
英文原题：Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024.
尽管嵌合抗原受体（CAR）T 细胞疗法已经彻底改变了淋巴系统恶性肿瘤的治疗格局，但其最大的挑战仍在于急性髓系白血病（AML）的治疗。
嵌合抗原受体（CAR）T细胞疗法改变了淋巴系统恶性肿瘤的治疗格局，但急性髓系白血病（AML）仍是最难攻克的领域。AML中CAR-T疗法的成功受理想靶抗原选择、骨髓抑制及白血病免疫抑制性微环境等因素限制。2024年美国血液学会（ASH）年会重点报告了多项AML靶向CAR-T疗法的前沿进展，包括针对CD33、CD123、CLL1、CD19和IL1RAP的临床试验，以及双靶向CAR、抑制型CAR和基因组编辑等旨在提高安全性和疗效的新工程策略。本文总结相关临床及临床前研究的关键发现，介绍AML CAR-T细胞疗法不断演变的研究格局。
While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for lymphoid malignancies, its greatest challenge remains in the treatment of acute myeloid leukemia (AML). Its success in AML has been limited by the ideal target antigen, myelosuppression, and immunosuppressive leukemia microenvironment. The 2024 ASH Meeting highlighted several cutting-edge advancements in AML-directed CAR T therapies, including clinical trials targeting CD33, CD123, CLL1, CD19, and IL1RAP, as well as novel engineering strategies such as dual-targeting CARs, inhibitory CAR designs, and genome-editing approaches to enhance safety and efficacy. Here, we summarize key findings from both clinical and preclinical studies, offering insights into the evolving landscape of CAR T-cell therapy for AML.
MEMBER ACCOUNT
登录成功会直接打开下一页。
